Cenegenics Complete Guide to Healthy Aging - (Page 39) Is hGH safe—are there side effects? Studies overwhelmingly point toward the safety of growth hormone therapy in hGH-deficient adults. Per a 999 article in the New England Journal of Medicine: “Side effects of growth hormone therapy for adult deficiency are minor, dose-related, and totally reversible.” Also, a cover story on growth hormone, published in a 003 issue of Newsweek, Dr. Pinchas Cohen, Director of Pediatric Endocrinology– UCLA, states “all the evidence shows that growth hormone is one of the safest drugs we have. Thousands of patients have been followed for the last years.” Of course, before starting on any hormonal therapy, a comprehensive evaluation is essential. Any program should focus on hormonal balance with careful monitoring to minimize the potential of mild side effects. These patent parameters make hGH manufacturing complex and pricey. However, adult-deficient patients must avoid the lure of “cheaper” hGH. Drug-dispensing Web sites sprawl across the Internet, promising deep discounts and “anti-aging hGH.” However, the government has drawn a clear line regarding steroid and hGH prescription and use, albeit via online or direct purchase. That’s evidenced by the flurry of grand jury indictments, followed by the Department of Justice and FDA raids on online drug networks linked to indiscriminate doctors and “antiaging” healthcare centers. Cenegenics—as a medical facility for age management, not part of the anti-aging trend—always has been compliant with the letter and intention of the law. We believe in the traditional approach of patients seeing their doctors and undergoing comprehensive exams to determine the appropriate therapy. Our physicians only prescribe hGH on label for proven adult hGH deficiency. IMPROVEd • cholesterol profile • memory • cognitive function BETTER • wound healing with lower infection rate STRENGTHENEd • immune system If your evaluation assessment shows an adult hGH deficiency, your personal Cenegenics physician will help you understand and assess all the available information, as objectively as possible. Experience has shown us that the benefit of growth hormone therapy for deficient adults far outweighs the risk. Ultimately, the decision is yours. iii. th e s CienCe B ehind Cen egeniCs WWW.CENEGENICS.COM 39 III. the science Behind Cenegenics It should also be noted that individuals with certain specific medical diagnoses should avoid growth hormone therapy for adult deficiency because it could exacerbate their illness. These contraindications include uncontrolled diabetes; unusual lung diseases, such as pulmonary fibrosis, sarcoidosis, pneumoconiosis and bronchiolitis obliterans; Hermansky-Pudlak Syndrome; or systemic sclerosis. Currently, growth hormone is contraindicated in the history of cancer. There is not sufficient medical literature to use hGH safely in this context—although we do believe that literature will appear in the not-too-distant future. If you have ever been diagnosed with any of these medical problems, be sure to inform your Cenegenics physician. HORMONE IN hGHdEFICIENT AdULTS STUdIEd & PUBLISHEd BENEFITS OF GROwTH dECREASEd • body fat • skin wrinkling • hospitalization rate by 50% • sick days from work • diastolic blood pressure • waist/hip ratio • bone loss, increases with age INCREASEd • libido • lean muscle • bone density • skin thickness • exercise capacity • renal blood flow • feeling of well-being/improved socialization An hGH distinction: FDA regulations. The FDA established strict regulations, limiting how human growth hormone (hGH) can be prescribed, manufactured, distributed and sold. The FDA actually licenses and oversees companies manufacturing hGH. These manufacturers must register and verify their methods and product, uniformity, bioavailability, safety and demonstrated effectiveness. Therefore, by federal law, any claim that a product contains hGH would require its production be overseen and approved by the FDA, meeting standards for quality and content. http://WWW.CENEGENICS.COM
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.